Market revenue in 2024 | USD 77.9 million |
Market revenue in 2030 | USD 53.1 million |
Growth rate | -6.7% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.48% in 2024. Horizon Databook has segmented the India anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
India’s anti-VEGF therapeutics market is anticipated to witness significant growth over the forecast period, owing to increasing prevalence of wet AMD and DME, coupled with increasing disposable income of the population. According to the Global Burden of Disease database, the prevalence of AMD was reported to be around 957,438 in 2018, which increased to 1,100,928 in 2019.
The penetration of biosimilars in the market can increase the affordability of treatment for middle-income patients in the region. In November 2017, Mylan N.V. (Viatris Inc.) introduced ABEVMY, a biosimilar version of bevacizumab after the Drug Controller General of India’s (DCGI) approval for Avastin-approved indications. The product is used off-label for the treatment of wet AMD.
Horizon Databook provides a detailed overview of country-level data and insights on the India anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into India anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account